Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical Testing, and III. Clinical Testing
Part I. Basic Principles. TB vaccines cannot prevent establishment of the infection. They can only prevent an early pulmonary tubercle from developing into clinical disease. A more effective new vaccine should optimize both cell-mediated immunity (CMI) and delayed-type hypersensitivity (DTH) better...
Main Authors: | Bappaditya Dey, Arthur M. Dannenberg |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-01-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-393X/1/1/58 |
Similar Items
-
Application Values of T-SPOT.TB in Clinical Rapid Diagnosis of Tuberculosis
by: Feng ZHU, et al.
Published: (2017-12-01) -
Drug-resistant tuberculosis: an experience from Qatar
by: Maisa Ali, et al.
Published: (2020-01-01) -
Detection of Tuberculosis in HIV Co-infected Individuals: Use of Multiple ELISA Responses to 38kDa, Lipoarabinomannan and ESAT– 6 of M. tuberculosis
by: Ravi Gutlapalli, et al.
Published: (2016-02-01) -
Proteins purified from Mycobacterium tuberculosis MDR and Susceptible clinical isolates: Identification by proteomics approach
by: A R. Hadizadeh Tasbiti, et al.
Published: (2015-01-01) -
Current and Novel Approaches to Vaccine Development Against Tuberculosis
by: Mark eCayabyab, et al.
Published: (2012-12-01)